LENZ Therapeutics, Inc. (LENZ) compared with its closest peers (DTIL, ABOS, CHRS, VYGR, PLX). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Precision BioSciences, Inc. (DTIL) | $244.27M | -1.2 |
| Acumen Pharmaceuticals, Inc. (ABOS) | $228.24M | -1.1 |
| Coherus Oncology, Inc. (CHRS) | $217.85M | 1.0 |
| Voyager Therapeutics, Inc. (VYGR) | $203.62M | -1.9 |
| Protalix BioTherapeutics, Inc. (PLX) | $190.55M | 10.1 |
| Armata Pharmaceuticals, Inc. (ARMP) | $188.51M | -1.3 |
| Caribou Biosciences, Inc. (CRBU) | $176.89M | -1.0 |
| Humacyte, Inc. (HUMA) | $164.24M | — |
| Invivyd, Inc. (IVVD) | $158.05M | -8.3 |
| Black Diamond Therapeutics, Inc. (BDTX) | $126.40M | 6.3 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
LENZ overview · LENZ earnings · LENZ financials · LENZ KPIs · LENZ investor relations · LENZ ownership · LENZ filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.